Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Tango Therapeutics (TNGX) Enterprise Value (2020 - 2025)

Tango Therapeutics has reported Enterprise Value over the past 6 years, most recently at -$112.7 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$112.7 million for Q4 2025, up 56.31% from a year ago — trailing twelve months through Dec 2025 was -$112.7 million (up 56.31% YoY), and the annual figure for FY2025 was -$112.7 million, up 56.31%.
  • Enterprise Value for Q4 2025 was -$112.7 million at Tango Therapeutics, up from -$152.8 million in the prior quarter.
  • Over the last five years, Enterprise Value for TNGX hit a ceiling of -$39.7 million in Q2 2025 and a floor of -$503.8 million in Q3 2021.
  • Median Enterprise Value over the past 5 years was -$129.1 million (2021), compared with a mean of -$195.1 million.
  • Biggest five-year swings in Enterprise Value: tumbled 203565.03% in 2021 and later surged 87.68% in 2025.
  • Tango Therapeutics' Enterprise Value stood at -$145.6 million in 2021, then soared by 58.42% to -$60.5 million in 2022, then decreased by 11.15% to -$67.3 million in 2023, then plummeted by 283.32% to -$257.9 million in 2024, then soared by 56.31% to -$112.7 million in 2025.
  • The last three reported values for Enterprise Value were -$112.7 million (Q4 2025), -$152.8 million (Q3 2025), and -$39.7 million (Q2 2025) per Business Quant data.